Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 8596 to 8610 of 9133 results

  1. Pembrolizumab with docetaxel for treating hormone-relapsed metastatic prostate cancer untreated with chemotherapy [ID3801]

    Discontinued Reference number: GID-TA10668

    Technology appraisal guidance
    Discontinued

  2. Selinexor for treating unresectable dedifferentiated advanced liposarcoma [ID3825]

    Discontinued Reference number: GID-TA10694

    Technology appraisal guidance
    Discontinued

  3. Pembrolizumab with olaparib for treating hormone-relapsed metastatic prostate cancer after abiraterone or enzalutamide and chemotherapy [ID3814]

    In development Reference number: GID-TA10696 Expected publication date: TBC

    Technology appraisal guidance
    In development

  4. Pembrolizumab with lenvatinib for untreated advanced melanoma [ID3948]

    Discontinued Reference number: GID-TA10848

    Technology appraisal guidance
    Discontinued

  5. Pralsetinib for thyroid cancer [ID4018]

    Discontinued Reference number: GID-TA10910

    Technology appraisal guidance
    Discontinued

  6. Nivolumab for neoadjuvant and adjuvant treatment of localised renal cell carcinoma [ID4047]

    Discontinued Reference number: GID-TA10927

    Technology appraisal guidance
    Discontinued

  7. Nivolumab with docetaxel for treating hormone-relapsed advanced prostate cancer after 1 or 2 hormonal therapies [ID4048]

    Discontinued Reference number: GID-TA10929

    Technology appraisal guidance
    Discontinued

  8. Belzutifan for previously treated advanced renal cell carcinoma [ID6154]

    Discontinued Reference number: GID-TA11086

    Technology appraisal guidance
    Discontinued

  9. BI 907828 for untreated dedifferentiated advanced liposarcoma [ID6296]

    Discontinued Reference number: GID-TA11344

    Technology appraisal guidance
    Discontinued

  10. Durvalumab with tremelimumab for treating limited-stage small-cell lung cancer after chemoradiation [ID5097]

    In development Reference number: GID-TA11214 Expected publication date: TBC

    Technology appraisal guidance
    In development

  11. Nivolumab with ipilimumab for untreated unresectable stage 3 non-small-cell lung cancer [ID6248]

    Discontinued Reference number: GID-TA11253

    Technology appraisal guidance
    Discontinued

  12. Telisotuzumab vedotin for treating c-MET overexpressed, EGFR wild-type, non-squamous advanced non-small-cell lung cancer after 1 or more systemic treatments [ID6253]

    In development Reference number: GID-TA11274 Expected publication date: TBC

    Technology appraisal guidance
    In development

  13. Datopotamab deruxtecan for treating advanced non-small-cell lung cancer after platinum-based chemotherapy [ID6241]

    Discontinued Reference number: GID-TA11277

    Technology appraisal guidance
    Discontinued

  14. Tiragolumab with atezolizumab for treating locally advanced unresectable stage 3 non-small-cell lung cancer after at least 2 cycles of platinum-based chemoradiation [ID6250]

    In development Reference number: GID-TA11278 Expected publication date: TBC

    Technology appraisal guidance
    In development

  15. Treatments for non-small-cell lung cancer [ID6234]

    Discontinued Reference number: GID-TA11289

    Technology appraisal guidance
    Discontinued